1
|
Cercos M, Seqat I, Facile A, Vial T, Auffret M. Lacosamide use during breastfeeding: A case report and a literature review. Fundam Clin Pharmacol 2024; 38:575-578. [PMID: 38054544 DOI: 10.1111/fcp.12971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2023] [Revised: 10/08/2023] [Accepted: 10/31/2023] [Indexed: 12/07/2023]
Abstract
Lacosamide, a voltage-gated sodium channel inhibitor, is an anti-seizure medication (ASM) from the age of 4. We report on the case of a woman treated with lacosamide for pharmacoresistant epilepsy who breastfed her infant for more than 6 months after birth. The infant's blood concentrations of lacosamide were 2.4 mg/L on Day 1 and less than 1 mg/L on Day 10 (reference values are 1-10 mg/L). No adverse drug reactions (ADRs) were reported for the infant. Eight cases of breastfeeding by mothers receiving lacosamide are described in the literature. These data confirm that a significant amount of lacosamide seems to pass into breast milk, with a relative infant dose (RID) above 20% in two cases but a low RID (1.8%) in another case. Nevertheless, blood tests, performed in two breastfed infants, revealed low concentrations of lacosamide. No ADRs were reported in eight of the breastfed infants; however, one infant, whose mother was also treated with levetiracetam, presented poor feeding and sleepiness at Day 15 of life. Given the well-known benefits of breastfeeding for both mothers and their infants, as well as the above reassuring data, breastfeeding of healthy full-term infants could be possible for mothers on lacosamide monotherapy. Nonetheless, relatives should be warned that data concerning the safety of lacosamide during breastfeeding are scarce and that long-term neurodevelopment outcomes in breastfed children are unknown. Clinical monitoring of breastfed infants for drowsiness, adequate weight gain, or cutaneous rash is recommended. Additionally, the infants' serum levels should be measured in case of an unexplained adverse reaction.
Collapse
Affiliation(s)
- Morgan Cercos
- Service Hospitalo-Universitaire de Pharmacotoxicologie, Hospices Civils de Lyon, Lyon, France
| | - Ines Seqat
- Service de neurologie fonctionnelle et épileptologie, hôpital neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France
| | - Anthony Facile
- Service Hospitalo-Universitaire de Pharmacotoxicologie, Hospices Civils de Lyon, Lyon, France
| | - Thierry Vial
- Service Hospitalo-Universitaire de Pharmacotoxicologie, Hospices Civils de Lyon, Lyon, France
| | - Marine Auffret
- Service Hospitalo-Universitaire de Pharmacotoxicologie, Hospices Civils de Lyon, Lyon, France
- UMR 5558, Laboratoire de Biométrie et Biologie Évolutive, Université Lyon 1, Lyon, France
| |
Collapse
|
2
|
Bertin B, Auffret M, Chabert P. Positive rechallenge of hemophagocytic lymphohistiocytosis in a patient treated with isoniazide, pembrolizumab, carboplatine and pemetrexed. Therapie 2023; 78:762-764. [PMID: 36682965 DOI: 10.1016/j.therap.2022.12.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2022] [Revised: 11/03/2022] [Accepted: 12/09/2022] [Indexed: 12/23/2022]
Affiliation(s)
- Blandine Bertin
- Pharmacovigilance Center, Hospital University Pharmacotoxicology Department, Hospices Civils de Lyon, 162, avenue Lacassagne, 69003 Lyon, France
| | - Marine Auffret
- Pharmacovigilance Center, Hospital University Pharmacotoxicology Department, Hospices Civils de Lyon, 162, avenue Lacassagne, 69003 Lyon, France; UMR 5558, Laboratoire de Biométrie et Biologie Evolutive, Université Lyon 1, 69003 Lyon, France.
| | - Paul Chabert
- Department of Infectious and Tropical Diseases, Croix Rousse Hospital, Hospices Civils de Lyon, 69003 Lyon, France
| |
Collapse
|
3
|
Jenner P, Falup-Pecurariu C, Leta V, Verin M, Auffret M, Bhidayasiri R, Weiss D, Borovečki F, Jost WH. Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson's disease. J Neural Transm (Vienna) 2023; 130:1337-1347. [PMID: 37210460 PMCID: PMC10645644 DOI: 10.1007/s00702-023-02655-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Accepted: 05/14/2023] [Indexed: 05/22/2023]
Abstract
Dopaminergic therapies dominate the treatment of the motor and non-motor symptoms of Parkinson's disease (PD) but there have been no major advances in therapy in many decades. Two of the oldest drugs used appear more effective than others-levodopa and apomorphine-but the reasons for this are seldom discussed and this may be one cause for a lack of progress. This short review questions current thinking on drug action and looks at whether adopting the philosophy of ex-US Secretary of State Donald Rumsfeld reveals 'unknown' aspects of the actions of levodopa and apomorphine that provide clues for a way forward. It appears that both levodopa and apomorphine have a more complex pharmacology than classical views would suggest. In addition, there are unexpected facets to the mechanisms through which levodopa acts that are either forgotten as 'known unknowns' or ignored as 'unknown unknowns'. The conclusion reached is that we may not know as much as we think about drug action in PD and there is a case for looking beyond the obvious.
Collapse
Affiliation(s)
- P Jenner
- Faculty of Life Sciences and Medicine, Institute of Pharmaceutical Sciences, King's College London, London, SE1 1UL, UK.
| | - C Falup-Pecurariu
- Department of Neurology, Transylvania University, 500036, Brasov, Romania
| | - V Leta
- Parkinson's Foundation Center of Excellence at King's College Hospital; Department of Basic and Clinical Neuroscience, The Maurice Wohl Clinical Neuroscience Institute, King's College London and National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre, Institute of Psychology, Psychiatry and Neurosciences, King's College London, London, UK
| | - M Verin
- Institut des Neurosciences Cliniques de Rennes (INCR); Behavior and Basal Ganglia Research Unit, CIC-IT, CIC1414, Pontchaillou University Hospital and University of Rennes, Rennes, France
| | - M Auffret
- Institut des Neurosciences Cliniques de Rennes (INCR); Behavior and Basal Ganglia Research Unit, CIC-IT, CIC1414, Pontchaillou University Hospital and University of Rennes, Rennes, France
- France Développement Electronique (FDE), Monswiller, France
| | - Roongroj Bhidayasiri
- Department of Medicine, Faculty of Medicine, Chulalongkorn Centre of Excellence for Parkinson's Disease and Related Disorders, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, 10330, Thailand
- The Academy of Science, The Royal Society of Thailand, Bangkok, 10330, Thailand
| | - D Weiss
- Department for Neurodegenerative Diseases, Centre for Neurology, Hertie-Institute for Clinical Brain Research, Hoppe-Seyler-Str. 3, 72076, Tübingen, Germany
| | - F Borovečki
- Division for Neurodegenerative Diseases and Neurogenomics, Department of Neurology, University Hospital Centre Zagreb, 10000, Zagreb, Croatia
| | - W H Jost
- Parkinson-Klinik Ortenau, Kreuzbergstr. 12-16, 77709, Wolfach, Germany
| |
Collapse
|
4
|
Facile A, Deliniere A, Auffret M, Vial T, Citterio-Quentin A, Chevalier P, Grenet G. Green tea and nadolol interaction: A risk of therapeutic inefficiency, a case report and extensive review. Therapie 2023:S0040-5957(23)00144-0. [PMID: 37951784 DOI: 10.1016/j.therap.2023.10.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Revised: 10/07/2023] [Accepted: 10/12/2023] [Indexed: 11/14/2023]
Affiliation(s)
- Anthony Facile
- Service hospitalo-universitaire de pharmacotoxicologie, Hospices civils de Lyon, 69000 Lyon, France.
| | - Antoine Deliniere
- Service de rythmologie, Centre national de référence des troubles du rythme cardiaque d'origine héréditaire de Lyon (CERA), Hospices civils de Lyon, 69500 Bron, France
| | - Marine Auffret
- Service hospitalo-universitaire de pharmacotoxicologie, Hospices civils de Lyon, 69000 Lyon, France; Laboratoire de biométrie et biologie évolutive UMR 5558, Université Lyon 1, CNRS, 69622 Villeurbanne, France
| | - Thierry Vial
- Service hospitalo-universitaire de pharmacotoxicologie, Hospices civils de Lyon, 69000 Lyon, France
| | - Antony Citterio-Quentin
- Centre de biologie sud, UM pharmaco-toxicologie, Hospices civils de Lyon, 69000 Lyon, France
| | - Philippe Chevalier
- Service de rythmologie, Centre national de référence des troubles du rythme cardiaque d'origine héréditaire de Lyon (CERA), Hospices civils de Lyon, 69500 Bron, France
| | - Guillaume Grenet
- Service hospitalo-universitaire de pharmacotoxicologie, Hospices civils de Lyon, 69000 Lyon, France; Laboratoire de biométrie et biologie évolutive UMR 5558, Université Lyon 1, CNRS, 69622 Villeurbanne, France
| |
Collapse
|
5
|
Pariente A, Micallef J, Lahouegue A, Molimard M, Auffret M, Chouchana L, Denis B, Faillie JL, Grandvuillemin A, Letinier L, Pierron E, Pons C, Pujade I, Rubino H, Salvo F. What place for intelligent automation and artificial intelligence to preserve and strengthen vigilance expertise in the face of increasing declarations? Therapie 2023; 78:131-143. [PMID: 36572627 DOI: 10.1016/j.therap.2022.11.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
In 2018, the "Ateliers de Giens" (Giens Workshops) devoted a workshop to artificial intelligence (AI) and led its experts to confirm the potential contribution and theoretical benefit of AI in clinical research, pharmacovigilance, and in improving the efficiency of care. The 2022 workshop is a continuation of this reflection on AI and intelligent automation (IA) by focusing on its contribution to pharmacovigilance and the applications and tasks could be optimized to preserve and strengthen medical and pharmacological expertise in pharmacovigilance. The evolution of pharmacovigilance work is characterized by many tasks with low added value, a growing volume of pharmacovigilance reporting of suspected side effects, and a scarcity of medical staff with expertise in clinical pharmacology and pharmacovigilance and human resources to support this growing need. Together, these parameters contribute to an embolization of the pharmacovigilance system at risk of missing its primary mission: to identify and characterize a risk or even a health alert on a drug. The participants of the workshop (representatives of the Regional Pharmacovigilance Centres (CRPV), the French National Agency for Safety of Medicinal Products (ANSM), patients, the pharmaceutical industry, or start-ups working in the development of AI in the field of medicine) shared their experiences, their pilot projects and their expectations on the expected potential, theoretical or proven, AI and IA. This work has made it possible to identify the needs and challenges that AI or IA represent, in the current or future modes of organization of pharmacovigilance activities. This approach led to the development of a SWOT matrix (strengths, weaknesses, opportunities, threats), a basis for reflection to identify critical points and consider four main recommendations: (1) preserve and develop business expertise in pharmacovigilance (including research and development in methods) with the integration of new technologies; (2) improve the quality of pharmacovigilance reports; (3) adapt technical and regulatory means; (4) implement a development strategy for AI and IA tools at the service of expertise.
Collapse
Affiliation(s)
- Antoine Pariente
- Univ. Bordeaux, Inserm, BPH, U1219, Equipe AHeaD, 33000 Bordeaux, France; CHU de Bordeaux, service de Pharmacologie Médicale, 33000 Bordeaux, France.
| | - Joëlle Micallef
- AMU INS Inserm 1106, centre régional de pharmacovigilance, pharmacologie clinique, APHM, 13005 Marseille, France
| | - Amir Lahouegue
- Pharmacovigilance et information médicale, AstraZeneca, 92400 Courbevoie, France
| | - Mathieu Molimard
- Univ. Bordeaux, Inserm, BPH, U1219, Equipe AHeaD, 33000 Bordeaux, France; CHU de Bordeaux, service de Pharmacologie Médicale, 33000 Bordeaux, France
| | - Marine Auffret
- Service hospitalo-universitaire de pharmacotoxicologie, centre régional de pharmacovigilance, hospices civils de Lyon, UMR CNRS 5558, université de Lyon 1, 69000 Lyon, France
| | - Laurent Chouchana
- Service de pharmacologie, centre-université Paris Cité, centre régional de pharmacovigilance, hôpital Cochin, AP-HP, 75014 Paris, France
| | - Bernard Denis
- Formation recherche, union francophone patients partenaire, 75012 Paris, France
| | - Jean Luc Faillie
- Inserm, département de pharmacologie médicale et toxicologie, centre régional de pharmacovigilance, institut Desbrest d'épidémiologie et de santé publique, CHU de Montpellier, université Montpellier, 34090 Montpellier, France
| | | | | | - Evelyne Pierron
- Agence nationale de sécurité du médicament et des produits de santé (ANSM), 93285 Saint-Denis, France
| | | | | | - Heather Rubino
- Pfizer, Inc, 235, East 42nd Street, NYC, NY, 10007 New York, USA
| | - Francesco Salvo
- Univ. Bordeaux, Inserm, BPH, U1219, Equipe AHeaD, 33000 Bordeaux, France; CHU de Bordeaux, service de Pharmacologie Médicale, 33000 Bordeaux, France
| |
Collapse
|
6
|
Svrcek M, Saillard C, Dubois R, Loiseau N, Mespoulhe P, Brulport F, Guillon J, Auffret M, Sefta M, Kamoun A, Courtiol P, Rossat S, Renaud F, Fouillet A, Wainrib G. 920P Blind validation of MSIntuit, an AI-based pre-screening tool for MSI detection from colorectal cancer H&E slides. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
7
|
Atzenhoffer M, Auffret M, Pegat A, Masmoudi K, Khouri C, Bertin B, Vial T. Guillain-Barré Syndrome Associated with COVID-19 Vaccines: A Perspective From Spontaneous Report Data. Clin Drug Investig 2022; 42:581-592. [PMID: 35676452 PMCID: PMC9177406 DOI: 10.1007/s40261-022-01164-4] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/10/2022] [Indexed: 01/08/2023]
Abstract
BACKGROUND AND OBJECTIVE The concern surrounding the association between Guillain-Barré syndrome (GBS) and vaccination has increased with the widespread use of COVID-19 vaccines. The aim of this study was to assess the potential association of GBS with mRNA-based or adenovirus-vectored COVID-19 vaccines. METHODS Reports of GBS associated with mRNA-based or adenovirus-vectored COVID-19 vaccines were extracted from the WHO pharmacovigilance database, exposure data from the Our World in Data website, and the background rates of GBS from published data. For countries contributing to VigiBase and with available data on COVID-19 vaccine exposure, reporting rates were estimated and observed-to-expected (OE) analyses were performed. RESULTS A total of 2499 cases were included: 1157 (46.3%) cases with adenovirus-vectored COVID-19 vaccines and 1342 (53.7%) with mRNA-based COVID-19 vaccines. The male-to-female sex ratio was 1.09 and the median (IQR) age was 57 (45-66) years. The reporting rates (95% CI) per 100,000 person-years within the 42-day window were 5.57 (5.13-6.03) for adenovirus-vectored COVID-19 vaccines and 1.39 (1.31-1.47) for mRNA-based COVID-19 vaccines, while the background incidence was 1.2-3.1 per 100,000 person-years. For mRNA-based COVID-19 vaccines, the OE ratio was <1 for both time windows in all European countries and slightly elevated for the 21-day window in the USA. For adenovirus-vectored COVID-19 vaccines, the OE ratio was consistently > 2.0 for all countries. Sensitivity analyses minimally altered these results. CONCLUSIONS These findings suggest both the absence of safety concern for GBS with mRNA-based COVID-19 vaccines and an increased risk with adenovirus-vectored COVID-19 vaccines. Back to top.
Collapse
Affiliation(s)
- Marina Atzenhoffer
- Pharmacovigilance Center, Hospital University Pharmacotoxicology Department, Hospices civils de Lyon, 162 avenue Lacassagne, 69003 Lyon, France
| | - Marine Auffret
- Pharmacovigilance Center, Hospital University Pharmacotoxicology Department, Hospices civils de Lyon, 162 avenue Lacassagne, 69003 Lyon, France
| | - Antoine Pegat
- Electroneuromyography and Neuromuscular Disorders Unit, Pierre Wertheimer Neurological Hospital, Hospices civils de Lyon, Lyon, France
| | - Kamel Masmoudi
- Clinical Pharmacology Department, Regional Pharmacovigilance Center, Amiens-Picardie University Hospital Center, Amiens, France
| | - Charles Khouri
- Clinical Pharmacology and Pharmacovigilance Department, Grenoble Alpes University Hospital, Grenoble, France
| | - Blandine Bertin
- Pharmacovigilance Center, Hospital University Pharmacotoxicology Department, Hospices civils de Lyon, 162 avenue Lacassagne, 69003 Lyon, France
| | - Thierry Vial
- Pharmacovigilance Center, Hospital University Pharmacotoxicology Department, Hospices civils de Lyon, 162 avenue Lacassagne, 69003 Lyon, France
| |
Collapse
|
8
|
Largeau B, Bordy R, Pasqualin C, Bredeloux P, Cracowski JL, Lengellé C, Gras-Champel V, Auffret M, Maupoil V, Jonville-Béra AP. Gabapentinoid-induced peripheral edema and acute heart failure: A translational study combining pharmacovigilance data and in vitro animal experiments. Biomed Pharmacother 2022; 149:112807. [PMID: 35303569 DOI: 10.1016/j.biopha.2022.112807] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2021] [Revised: 02/20/2022] [Accepted: 03/07/2022] [Indexed: 11/25/2022] Open
Abstract
INTRODUCTION Gabapentinoids are ligands of the α2-δ subunit of voltage-gated calcium channels (Cav) that have been associated with a risk of peripheral edema and acute heart failure in connection with a potentially dual mechanism, vascular and cardiac. OBJECTIVES & METHODS All cases of peripheral edema or heart failure involving gabapentin or pregabalin reported to the French Pharmacovigilance Centers between January 1, 1994 and April 30, 2020 were included to describe their onset patterns (e.g., time to onset). Based on these data, we investigated the impact of gabapentinoids on the myogenic tone of rat third-order mesenteric arteries and on the electrophysiological properties of rat ventricular cardiomyocytes. RESULTS A total of 58 reports were included (gabapentin n = 5, pregabalin n = 53). The female-to-male ratio was 4:1 and the median age was 77 years (IQR 57-85, range 32-95). The median time to onset were 23 days (IQR 10-54) and 17 days (IQR 3-30) for non-cardiogenic edema and acute heart failure, respectively. Cardiogenic and non-cardiogenic peripheral edema occurred frequently after a dose escalation (27/45, 60%), and the course was rapidly favorable after discontinuation of gabapentinoid (median 7 days, IQR 5-13). On rat mesenteric arteries, gabapentinoids significantly decreased the myogenic tone to the same extent as verapamil and nifedipine. Acute application of gabapentinoids had no significant effect on Cav1.2 currents of ventricular cardiomyocytes. CONCLUSION Gabapentinoids can cause concentration-dependent peripheral edema of early onset. The primary mechanism of non-cardiogenic peripheral edema is vasodilatory edema secondary to altered myogenic tone, independent of Cav1.2 blockade under the experimental conditions tested.
Collapse
Affiliation(s)
- Bérenger Largeau
- CHRU de Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance Centre-Val de Loire, Tours 37044, France.
| | - Romain Bordy
- Université de Tours, Transplantation, Immunologie et Inflammation (T2I) - EA4245, Tours 37044, France.
| | - Côme Pasqualin
- Université de Tours, Transplantation, Immunologie et Inflammation (T2I) - EA4245, Tours 37044, France.
| | - Pierre Bredeloux
- Université de Tours, Transplantation, Immunologie et Inflammation (T2I) - EA4245, Tours 37044, France.
| | - Jean-Luc Cracowski
- CHU Grenoble Alpes, Centre Régional de Pharmacovigilance et d'Information sur les Médicaments, Grenoble 38000, France; University of Grenoble HP2, INSERM, Grenoble, 38000, France.
| | - Céline Lengellé
- CHRU de Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance Centre-Val de Loire, Tours 37044, France.
| | - Valérie Gras-Champel
- CHU d'Amiens, Service de Pharmacologie Clinique, Centre Régional de Pharmacovigilance d'Amiens, Amiens 80054, France.
| | - Marine Auffret
- Hospices Civils de Lyon, Service Hospitalo-Universitaire de Pharmacotoxicologie, Centre Régional de Pharmacovigilance, Lyon, France.
| | - Véronique Maupoil
- Université de Tours, Transplantation, Immunologie et Inflammation (T2I) - EA4245, Tours 37044, France.
| | - Annie-Pierre Jonville-Béra
- CHRU de Tours, Service de Pharmacosurveillance, Centre Régional de Pharmacovigilance Centre-Val de Loire, Tours 37044, France; Université de Tours, Université de Nantes, INSERM, methodS in Patients-centered outcomes and HEalth ResEarch (SPHERE) - UMR 1246, Tours 37044, France.
| |
Collapse
|
9
|
Reverchon J, Auffret M, Grenet G, Nguyen KA. A survey of health professionals' opinion about web and smartphone application in clinical toxicology training. Toxicol Lett 2021. [DOI: 10.1016/s0378-4274(21)00563-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
10
|
Jarrier N, Paret N, Bret B, Couette A, Morel I, Auffret M. Intoxication phalloïdienne chez une femme allaitante : quelles conséquences pour le bébé ? À propos d’un cas. Toxicologie Analytique et Clinique 2021. [DOI: 10.1016/j.toxac.2021.06.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Bultelle F, Boutet I, Devin S, Caza F, St-Pierre Y, Péden R, Brousseau P, Chan P, Vaudry D, Le Foll F, Fournier M, Auffret M, Rocher B. Molecular response of a sub-antarctic population of the blue mussel (Mytilus edulis platensis) to a moderate thermal stress. Mar Environ Res 2021; 169:105393. [PMID: 34217095 DOI: 10.1016/j.marenvres.2021.105393] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/16/2020] [Revised: 06/08/2021] [Accepted: 06/14/2021] [Indexed: 06/13/2023]
Abstract
The Kerguelen Islands (49°26'S, 69°50'E) represent a unique environment due to their geographical isolation, which protects them from anthropogenic pollution. The ability of the endemic mussel, part of the Mytilus complex, to cope with moderate heat stress was explored using omic tools. Transcripts involved in six major metabolic functions were selected and the qRT-PCR data indicated mainly changes in aerobic and anaerobic energy metabolism and stress response. Proteomic comparisons revealed a typical stress response pattern with cytoskeleton modifications and elements suggesting increased energy metabolism. Results also suggest conservation of protein homeostasis by the long-lasting presence of HSP while a general decrease in transcription is observed. The overall findings are consistent with an adaptive response to moderate stresses in mussels in good physiological condition, i.e. living in a low-impact site, and with the literature concerning this model species. Therefore, local blue mussels could be advantageously integrated into biomonitoring strategies, especially in the context of Global Change.
Collapse
Affiliation(s)
- F Bultelle
- UMR-I 02 INERIS-URCA-ULH SEBIO / Environmental Stresses and Biomonitoring of Aquatic Ecosystems, FR CNRS 3730 Scale, Université Le Havre Normandie, F-76063, Le Havre Cedex, France.
| | - I Boutet
- Station Biologique de Roscoff CNRS, Laboratory Adaptation & Diversity in Marine Environment (UMR7144 CNRS-SU), Sorbonne Université, Roscoff, France.
| | - S Devin
- UMR 7360 LIEC, Université Metz-Lorraine, France.
| | - F Caza
- INRS-Institut Armand-Frappier, 531 Boul. des Prairies, Laval, Québec, H7V 1B7, Canada.
| | - Y St-Pierre
- INRS-Institut Armand-Frappier, 531 Boul. des Prairies, Laval, Québec, H7V 1B7, Canada.
| | - R Péden
- UMR-I 02 INERIS-URCA-ULH SEBIO / Environmental Stresses and Biomonitoring of Aquatic Ecosystems, FR CNRS 3730 Scale, Université Le Havre Normandie, F-76063, Le Havre Cedex, France; UMR-I 02 INERIS-URCA-ULH SEBIO / Environmental Stresses and Biomonitoring of Aquatic Ecosystems, Université de REIMS Champagne-Ardenne, Campus Moulin de la Housse, 51687, Reims, France.
| | - P Brousseau
- Institut des Sciences de la mer, Le Parc de la rivière Mitis, Sainte-Flavie, Québec, G0J 2L0, Canada.
| | - P Chan
- Normandie Univ, UNIROUEN, Plateforme PISSARO, IRIB, 76821, Mont-Saint-Aignan, France.
| | - D Vaudry
- Normandie Univ, UNIROUEN, Plateforme PISSARO, IRIB, 76821, Mont-Saint-Aignan, France; Normandie Univ, UNIROUEN, INSERM U1239 DC2N, 76821, Mont-Saint-Aignan, France.
| | - F Le Foll
- UMR-I 02 INERIS-URCA-ULH SEBIO / Environmental Stresses and Biomonitoring of Aquatic Ecosystems, FR CNRS 3730 Scale, Université Le Havre Normandie, F-76063, Le Havre Cedex, France.
| | - M Fournier
- Institut des Sciences de la mer, Le Parc de la rivière Mitis, Sainte-Flavie, Québec, G0J 2L0, Canada.
| | - M Auffret
- UMR CNRS 6539-LEMAR/ Laboratoire des Sciences de l'Environnement Marin, Technopôle Brest-Iroise, 29280, Plouzané, France.
| | - B Rocher
- UMR-I 02 INERIS-URCA-ULH SEBIO / Environmental Stresses and Biomonitoring of Aquatic Ecosystems, FR CNRS 3730 Scale, Université Le Havre Normandie, F-76063, Le Havre Cedex, France.
| |
Collapse
|
12
|
Grenet G, Mekhaldi S, Mainbourg S, Auffret M, Cornu C, Cracowski JL, Gueyffier F, Lega JC, Cucherat M. DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials. Diabetes Care 2021; 44:e36-e37. [PMID: 33436399 DOI: 10.2337/dc20-2018] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/14/2020] [Accepted: 11/19/2020] [Indexed: 02/03/2023]
Affiliation(s)
- Guillaume Grenet
- Service Hospitalo-Universitaire de Pharmacotoxicologie, Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France .,Laboratoire de Biométrie et Biologie Evolutive UMR 5558, CNRS, Université Lyon 1, Université de Lyon, Villeurbanne, France
| | - Samia Mekhaldi
- Laboratoire de Biométrie et Biologie Evolutive UMR 5558, CNRS, Université Lyon 1, Université de Lyon, Villeurbanne, France
| | - Sabine Mainbourg
- Laboratoire de Biométrie et Biologie Evolutive UMR 5558, CNRS, Université Lyon 1, Université de Lyon, Villeurbanne, France.,Service de Médecine Interne et Vasculaire, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Marine Auffret
- Service Hospitalo-Universitaire de Pharmacotoxicologie, Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France.,Laboratoire de Biométrie et Biologie Evolutive UMR 5558, CNRS, Université Lyon 1, Université de Lyon, Villeurbanne, France
| | - Catherine Cornu
- Laboratoire de Biométrie et Biologie Evolutive UMR 5558, CNRS, Université Lyon 1, Université de Lyon, Villeurbanne, France.,CIC1407 INSERM, Hospices Civils de Lyon, Lyon, France
| | - Jean-Luc Cracowski
- HP2, INSERM, Université Grenoble Alpes, and Centre régional de pharmacovigilance de Grenoble, Grenoble, France
| | - François Gueyffier
- Laboratoire de Biométrie et Biologie Evolutive UMR 5558, CNRS, Université Lyon 1, Université de Lyon, Villeurbanne, France
| | - Jean-Christophe Lega
- Laboratoire de Biométrie et Biologie Evolutive UMR 5558, CNRS, Université Lyon 1, Université de Lyon, Villeurbanne, France.,Service de Médecine Interne et Vasculaire, Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon, France
| | - Michel Cucherat
- Service Hospitalo-Universitaire de Pharmacotoxicologie, Pôle Santé Publique, Hospices Civils de Lyon, Lyon, France.,Laboratoire de Biométrie et Biologie Evolutive UMR 5558, CNRS, Université Lyon 1, Université de Lyon, Villeurbanne, France
| |
Collapse
|
13
|
|
14
|
Vial T, Auffret M, Cucherat M, Cottin J. Safety of statins in the first trimester of pregnancy: an updated meta-analysis. Reprod Toxicol 2019. [DOI: 10.1016/j.reprotox.2019.05.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
15
|
Auffret M, Cottin J, Vial T, Cucherat M. Clomiphene citrate and neural tube defects: a meta‐analysis of controlled observational studies. BJOG 2019; 126:1127-1133. [DOI: 10.1111/1471-0528.15800] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/11/2019] [Indexed: 01/19/2023]
Affiliation(s)
- M Auffret
- Service Hospitalo‐Universitaire de Pharmaco‐Toxicologie Hospices Civils de Lyon Lyon France
| | - J Cottin
- Service Hospitalo‐Universitaire de Pharmaco‐Toxicologie Hospices Civils de Lyon Lyon France
| | - T Vial
- Service Hospitalo‐Universitaire de Pharmaco‐Toxicologie Hospices Civils de Lyon Lyon France
| | - M Cucherat
- Service Hospitalo‐Universitaire de Pharmaco‐Toxicologie Hospices Civils de Lyon Lyon France
- Laboratoire de Biométrie & Biologie Evolutive Département Biostatistiques & Modélisation pour la Santé et l'Environnement Equipe Evaluation et Modélisation des Effets des Médicaments CNRS – Université Lyon 1 – UMR5558 Lyon France
| |
Collapse
|
16
|
Diallo I, Auffret M, Deloire L, Saccardy C, Aho S, Ben Salem D. Is dual-energy computed tomography helpful to determinate the ferromagnetic property of bullets? ACTA ACUST UNITED AC 2018. [DOI: 10.1016/j.jofri.2018.10.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
17
|
Auffret M, Cottin J, Gouraud A, Cucherat M. Clomiphene citrate and neural tube defects: A meta-analysis of controlled observational studies. Reprod Toxicol 2018. [DOI: 10.1016/j.reprotox.2018.07.067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
18
|
Denis Prevot M, Thillard E, Walther J, Veyrac G, Laroche M, Gautier S, Auffret M. Pristinamycin-induced arthralgia and myalgia: Analysis of the French Pharmacovigilance Database. Med Mal Infect 2018; 48:58-62. [DOI: 10.1016/j.medmal.2017.09.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2016] [Revised: 12/28/2016] [Accepted: 09/21/2017] [Indexed: 10/18/2022]
|
19
|
Auffret M, Rolland B, Caous AS, Gaboriau L, Deheul S, Bordet R, Gautier S. On-the-ground application of the ‘temporary recommendation for use’ regulatory measure on off-label use of baclofen for alcohol dependence in France: a regional survey of community pharmacies. Fundam Clin Pharmacol 2017; 32:234-238. [DOI: 10.1111/fcp.12332] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2017] [Revised: 10/02/2017] [Accepted: 11/09/2017] [Indexed: 11/28/2022]
Affiliation(s)
- Marine Auffret
- Centre Régional de Pharmacovigilance; CHU de Lille; 1 place de Verdun F-59037 Lille Cedex France
| | - Benjamin Rolland
- Service d'Addictologie; Hôpital Fontan 2; CHU de Lille; F-59037 Lille France
- INSERM U1171; Université de Lille; 1 place de Verdun F-59045 Lille France
| | - Anne-Sylvie Caous
- Centre d'Evaluation et d'Information sur la Pharmacodépendance de Lille; CHU de Lille; 1 place de Verdun F-59037 Lille Cedex France
| | - Louise Gaboriau
- Centre Régional de Pharmacovigilance; CHU de Lille; 1 place de Verdun F-59037 Lille Cedex France
| | - Sylvie Deheul
- Centre d'Evaluation et d'Information sur la Pharmacodépendance de Lille; CHU de Lille; 1 place de Verdun F-59037 Lille Cedex France
| | - Régis Bordet
- Centre Régional de Pharmacovigilance; CHU de Lille; 1 place de Verdun F-59037 Lille Cedex France
- INSERM U1171; Université de Lille; 1 place de Verdun F-59045 Lille France
- Centre d'Evaluation et d'Information sur la Pharmacodépendance de Lille; CHU de Lille; 1 place de Verdun F-59037 Lille Cedex France
| | - Sophie Gautier
- Centre Régional de Pharmacovigilance; CHU de Lille; 1 place de Verdun F-59037 Lille Cedex France
- INSERM U1171; Université de Lille; 1 place de Verdun F-59045 Lille France
| |
Collapse
|
20
|
Lacroix C, Duvieilbourg E, Guillou N, Guyomarch J, Bassoulet C, Moraga D, Chapalain G, Auffret M. Seasonal monitoring of blue mussel (Mytilus spp.) populations in a harbor area: A focus on responses to environmental factors and chronic contamination. Mar Environ Res 2017; 129:24-35. [PMID: 28431764 DOI: 10.1016/j.marenvres.2017.04.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/07/2016] [Revised: 04/07/2017] [Accepted: 04/10/2017] [Indexed: 06/07/2023]
Abstract
Coastal waters corresponding to macrotidal systems are among the most variable marine biotopes. Sessile animals as bivalve mollusks may however be found forming intertidal beds at high densities, as allowed by full adaptation to local conditions. A better knowledge of adaptive responses to environmental factors is required to foresee possible adverse effects of global change. At the sub-cellular level, transcriptional responses are among the earliest signals of environmental disturbances and they can reveal subtle and meaningful changes in organism exposed to stress. Three blue mussel (Mytilus spp.) populations inhabiting the Bay of Brest (France) in sites exposed to different levels of chronic pollution, from low to moderate, were surveyed upon a seasonal schedule, with special attention to the reproductive cycle. Major seawater parameters were monitored over a full-year in the framework of the S!RANO project, based on an automatic high frequency acquisition system installed aboard a ship of opportunity. The health status of mussels has been assessed by measuring a condition index and gametogenesis has been followed by histology. Selected biological responses to environmental stress were detected using a multimarker approach including expression of genes involved in chemical stress response and energetic metabolism, and cellular immune parameters. Environmental parameters showed deep seasonal variations which differed among sites. Most biological responses followed a seasonal pattern. Late winter and spring corresponded to an active reproduction period in the Bay of Brest. Earlier spawning was observed in harbor areas compared to the oceanic site and an altered physiological state was assumed in commercial harbor mussels during the reproductive period, suggesting that their health is compromised at this time of year. However, no signs of severe chemical stress were detected in both harbor mussel populations, which could reflect adaptive responses to adverse environmental conditions.
Collapse
Affiliation(s)
- C Lacroix
- LEMAR, UMR 6539 UBO/CNRS/IRD/Ifremer, Institut Universitaire Européen de la Mer, Université de Bretagne Occidentale, 29280 Plouzané, France; CEDRE, 715, Rue Alain Colas/CS 41836, 29218 Brest Cedex 2, France
| | - E Duvieilbourg
- LEMAR, UMR 6539 UBO/CNRS/IRD/Ifremer, Institut Universitaire Européen de la Mer, Université de Bretagne Occidentale, 29280 Plouzané, France
| | - N Guillou
- LGCE, CEREMA, 29280 Plouzané, France
| | - J Guyomarch
- CEDRE, 715, Rue Alain Colas/CS 41836, 29218 Brest Cedex 2, France
| | - C Bassoulet
- LDO, UMR 6538 UBO/CNRS, Institut Universitaire Européen de la Mer, Université de Bretagne Occidentale, 29280 Plouzané, France
| | - D Moraga
- LEMAR, UMR 6539 UBO/CNRS/IRD/Ifremer, Institut Universitaire Européen de la Mer, Université de Bretagne Occidentale, 29280 Plouzané, France
| | | | - M Auffret
- LEMAR, UMR 6539 UBO/CNRS/IRD/Ifremer, Institut Universitaire Européen de la Mer, Université de Bretagne Occidentale, 29280 Plouzané, France.
| |
Collapse
|
21
|
Pignon B, Labreuche J, Auffret M, Gautier S, Deheul S, Simioni N, Cottencin O, Bordet R, Duhamel A, Rolland B. The dose-effect relationship of baclofen in alcohol dependence: A 1-year cohort study. Hum Psychopharmacol 2017; 32. [PMID: 28517239 DOI: 10.1002/hup.2593] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/29/2016] [Revised: 12/15/2016] [Accepted: 03/16/2017] [Indexed: 01/06/2023]
Abstract
OBJECTIVE Our aim is to study the relationship between dose of baclofen and effectiveness in alcohol dependence. METHODS Two hundred two patients with alcohol dependence, who received baclofen treatment for drinking reduction, were followed up for 1 year. For each patient-month of treatment, the maximum daily dose of baclofen (DDB) and average weekly alcohol consumption (AWAC) were calculated. We defined a favorable drinking outcome as an AWAC under 200 g/w for at least 2 consecutive months. We divided the DDB of each patient-month into 3 categories (low dose: <90 mg/d, medium dose: 90-150 mg/d, and high dose: >150 mg/d) and investigated the relationship between reaching a favorable outcome and the concurrent DDB category in a time-varying Cox regression analysis. Hazard ratios (HRs) were adjusted based on age, sex, and initial AWAC. RESULTS One hundred forty subjects were followed during at least 1 month. Of these patients, 58 (41%) had a favorable drinking outcome. In comparison to low dose, medium dose was associated with a decreased rate of favorable drinking outcome (HR = 0.42; 95% CI [0.20, 0.88]), whereas no difference was found with high dose (HR = 1.31; 95% CI [0.65, 2.64]). CONCLUSION The relationship between dose of baclofen and favorable drinking outcome was U-shaped, that is, was increased at low and high doses compared to medium doses.
Collapse
Affiliation(s)
- Baptiste Pignon
- Psychiatry and Addiction Medicine Department, CHU Lille, Lille, France
| | - Julien Labreuche
- Department of Biostatistics, Univ. Lille, CHU Lille, EA 2694 - Santé publique : épidémiologie et qualité des soins, Lille, France
| | - Marine Auffret
- INSERM U1171, pharmacovigilance - addictovigilance, Univ. Lille, Lille, France
| | - Sophie Gautier
- INSERM U1171, pharmacovigilance - addictovigilance, Univ. Lille, Lille, France
| | - Sylvie Deheul
- INSERM U1171, pharmacovigilance - addictovigilance, Univ. Lille, Lille, France
| | - Nicolas Simioni
- Psychiatry and Addiction Medicine Department, CHU Lille, Lille, France
| | - Olivier Cottencin
- Psychiatry and Addiction Medicine Department, CHU Lille, Lille, France.,CNRS, UMR 9193, SCALab - PsyCHIC Team, Univ. Lille, Lille, France
| | - Régis Bordet
- INSERM U1171, pharmacovigilance - addictovigilance, Univ. Lille, Lille, France
| | - Alain Duhamel
- Department of Biostatistics, Univ. Lille, CHU Lille, EA 2694 - Santé publique : épidémiologie et qualité des soins, Lille, France.,CERIM, Univ. Lille, Lille, France
| | - Benjamin Rolland
- Psychiatry and Addiction Medicine Department, CHU Lille, Lille, France.,INSERM U1171, pharmacovigilance - addictovigilance, Univ. Lille, Lille, France
| |
Collapse
|
22
|
Caza F, Betoulle S, Auffret M, Brousseau P, Fournier M, St-Pierre Y. Comparative Sequence Analysis of Hsp70 Gene from Mytilus Edulis Desolationis and Aulacomya ater of the Kerguelen Islands. J Xenobiot 2016; 6:6721. [PMID: 30701056 PMCID: PMC6324491 DOI: 10.4081/xeno.2016.6721] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Affiliation(s)
- F Caza
- INRS-Institut Armand-Frappier, Laval, Québec, Canada
| | - S Betoulle
- Université Reims Champagne-Ardenne, UMR-I 02 SEBIO Stress environnementaux et Biosurveillance des milieux aquatiques, Reims, France
| | - M Auffret
- Laboratoire des Sciences de l'Environnement Marin, UMR CNRS 6539-LEMAR, Plouzane, France
| | - P Brousseau
- INRS-Institut Armand-Frappier, Laval, Québec, Canada
| | - M Fournier
- INRS-Institut Armand-Frappier, Laval, Québec, Canada
| | - Y St-Pierre
- INRS-Institut Armand-Frappier, Laval, Québec, Canada
| |
Collapse
|
23
|
Rolland B, Auffret M, Labreuche J, Lapeyre-Mestre M, Dib M, Kemkem A, Grit I, Drelon M, Duhamel A, Cabe N, Vabret F, Guillin O, Baguet A, Masquelier C, Dervaux A, Deheul S, Bordet R, Carton L, Cottencin O, Jardri R, Gautier S. Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder: the BACLOPHONE cohort study protocol. Expert Opin Drug Saf 2016; 16:125-132. [PMID: 27984918 DOI: 10.1080/14740338.2017.1270939] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
BACKGROUND In France, baclofen is frequently used off-label for alcohol use disorder (AUD). Baclofen has been associated with diverse adverse events (AEs), but the causality of these AEs has never been properly assessed. METHODS/DESIGN BACLOPHONE is a prospective multicenter cohort study conducted in the Hauts-de-France and Normandie French regions. BACLOPHONE consists of the phone-based monitoring of 792 patients during their first year of baclofen treatment for AUD. Two initial phone interviews assess the medical history, current medications, and substance use as well as complete the alcohol use identification test (AUDIT) and severity of alcohol dependence questionnaire (SADQ). Daily alcohol use and baclofen doses are noted throughout the follow-up. For every reported AE, additional phone interviews determine the seriousness of the AE, the causality of baclofen using validated causality algorithms, and the final outcome. The main objective of the study is to determine the rate of patients who stop baclofen due to an AE during the first year of treatment. DISCUSSION BACLOPHONE will provide important safety data on baclofen as a complement to the forthcoming efficacy data of randomized clinical trials.
Collapse
Affiliation(s)
- Benjamin Rolland
- a Département de Pharmacologie Médicale , INSERM U 1171, Univ Lille , Lille , France.,b Service d'Addictologie, CHU Lille , Lille , France
| | - Marine Auffret
- c Centre Régional de Pharmacovigilance, CHU Lille , Lille , France
| | - Julien Labreuche
- d Plateforme d'Aide Méthodologique , Biostatistique et Datamanagement, CHU Lille , Lille , France
| | - Maryse Lapeyre-Mestre
- e Service de Pharmacologie Clinique, CEIP-Addictovigilance, CIC 1436, CHU de ToulouseUMR-INSERM 1027 Universite Paul Sabatier - Toulouse 3 , Toulouse , France
| | - Malek Dib
- f Fédération de Recherche Clinique, CHU Lille , Lille , France
| | - Aomar Kemkem
- f Fédération de Recherche Clinique, CHU Lille , Lille , France
| | - Isabelle Grit
- f Fédération de Recherche Clinique, CHU Lille , Lille , France
| | - Marie Drelon
- g Centre d'Investigation Clinique, CHU Lille , Lille , France
| | - Alain Duhamel
- d Plateforme d'Aide Méthodologique , Biostatistique et Datamanagement, CHU Lille , Lille , France.,h CERIM, EA 2694, Univ Lille , Lille , France
| | - Nicolas Cabe
- i Service d'Addictologie, CHU de Caen , Caen , France
| | | | - Olivier Guillin
- k Centre Hospitalier du Rouvray, CHU de Rouen , Rouen , France
| | | | - Céline Masquelier
- p Centre Hospitalier Regional Universitaire de Lille Ringgold standard institution - Biostatistics CHU Lille , Lille , France
| | - Alain Dervaux
- l Service d'Addictologie, CHU d'Amiens , Amiens , France
| | - Sylvie Deheul
- m Centre d'Evaluation et d'Information sur les Pharmacodépendances, CHU Lille , Lille , France
| | - Régis Bordet
- a Département de Pharmacologie Médicale , INSERM U 1171, Univ Lille , Lille , France.,c Centre Régional de Pharmacovigilance, CHU Lille , Lille , France.,m Centre d'Evaluation et d'Information sur les Pharmacodépendances, CHU Lille , Lille , France
| | - Louise Carton
- a Département de Pharmacologie Médicale , INSERM U 1171, Univ Lille , Lille , France
| | - Olivier Cottencin
- b Service d'Addictologie, CHU Lille , Lille , France.,n SCALab UMR CNRS 9193, Univ Lille , Lille , France
| | - Renaud Jardri
- n SCALab UMR CNRS 9193, Univ Lille , Lille , France.,o Centre Universitaire de Recherche et d'Exploration, CHU Lille , Lille , France
| | - Sophie Gautier
- a Département de Pharmacologie Médicale , INSERM U 1171, Univ Lille , Lille , France.,c Centre Régional de Pharmacovigilance, CHU Lille , Lille , France
| |
Collapse
|
24
|
Rochoy M, Auffret M, Béné J, Gautier S. [Antiemetics and cardiac effects potentially linked to prolongation of the QT interval: Case/non-case analysis in the national pharmacovigilance database]. Rev Epidemiol Sante Publique 2016; 65:1-8. [PMID: 27988172 DOI: 10.1016/j.respe.2016.06.335] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2015] [Revised: 06/01/2016] [Accepted: 06/21/2016] [Indexed: 12/12/2022] Open
Abstract
OBJECTIVES Observational retrospective studies have linked domperidone and prolonged QT interval, ventricular arrhythmias and risk of sudden death. Since then, antiemetic prescription was applied to other molecules (including metopimazine). The aim of this study was to evaluate the profile of adverse cardiac effects associated with QT prolongation for each antiemetic available in France. METHODS We conducted disproportionality analyses (case/non-case method), based on the observations recorded consecutively in the French national pharmacovigilance database between 2004 and 2013. Cases were defined by following MedDRA terms: prolongation of the QT interval, syncope, sudden death, cardiac arrest, ventricular arrhythmias including torsades de pointes; non-cases were other adverse events reported during the same period. We analyzed the presence of each antiemetic among cases and non-cases and measured the disproportionality by reporting odds ratios (ROR). We validate the assay with a positive control (methadone) and a negative control (acetaminophen). RESULTS We compared 2093 cases (94 with antiemetics) to 253,665 non-cases (7015 with antiemetics). Among antiemetics, adverse cardiac effects studied were more frequently found with notifications including domperidone (ROR=2.0, 95% CI=[1.3; 3.0]), ondansetron (ROR=1.8, 95% CI=[1.3; 2.6]) and granisetron (ROR=3.4, 95% CI=[1.5; 7.6]). Metopimazine was not statistically associated with that risk (ROR=2.0; 95% CI=[0.8; 4.8]). CONCLUSION We confirmed a risk of cardiac adverse event related to prolongation of the QT interval with domperidone and setrons. These results suggest caution when prescribing antiemetics and encourage systematic reporting of adverse cardiac effects observed with these molecules.
Collapse
Affiliation(s)
- M Rochoy
- Département de médecine générale, université de Lille, 59000 Lille, France; Inserm, U1171, degenerative and vascular cognitive disorders, 59000 Lille, France.
| | - M Auffret
- Inserm, U1171, degenerative and vascular cognitive disorders, 59000 Lille, France; Centre régional de pharmacovigilance, CHU de Lille, faculté de médecine, 1, place de Verdun, 59000 Lille, France
| | - J Béné
- Inserm, U1171, degenerative and vascular cognitive disorders, 59000 Lille, France; Centre régional de pharmacovigilance, CHU de Lille, faculté de médecine, 1, place de Verdun, 59000 Lille, France
| | - S Gautier
- Inserm, U1171, degenerative and vascular cognitive disorders, 59000 Lille, France; Centre régional de pharmacovigilance, CHU de Lille, faculté de médecine, 1, place de Verdun, 59000 Lille, France
| | | |
Collapse
|
25
|
Kerambrun E, Rioult D, Delahaut L, Evariste L, Pain-Devin S, Auffret M, Geffard A, David E. Variations in gene expression levels in four European zebra mussel, Dreissena polymorpha, populations in relation to metal bioaccumulation: A field study. Ecotoxicol Environ Saf 2016; 134P1:53-63. [PMID: 27588554 DOI: 10.1016/j.ecoenv.2016.08.018] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/02/2016] [Revised: 08/22/2016] [Accepted: 08/23/2016] [Indexed: 06/06/2023]
Abstract
The present study was performed to validate the suitability of using gene expression in zebra mussels, Dreissena polymorpha, for biomonitoring of freshwater environment. Mussels were collected in four French rivers (Meuse, Moselle, Oise and Vilaine) in spring and autumn. Relative gene expression of 9 candidate genes involved in cellular metabolic activities (Cytochrome-c-oxidase - cox, and ATP synthase - atp), detoxification process (Metallothionein - mt and Glutathion-S-Transferase - gst), oxidative stress (Catalase - cat, Superoxyde Dismutase - sod and Glutathion peroxidase - gpx) and digestive functions (Amylase - amy and Cellulase - ghf) were measured in digestive gland. Metal bioaccumulation in tissues and morphometric parameters were also analyzed to interpret molecular responses. All our results are consistent with different physiological reactions to environmental condition between zebra mussel populations. In spring, the levels of mt, sod, gpx, cat, atp, amy and ghf relative expression were significantly higher in mussels with the lowest metal bioaccumulation (the Meuse) compared to at least one of the other sites. In autumn, this higher expression levels in Meuse River were still observed for gpx, cat, atp and amy. This study has also pointed out different sources of variability in gene expression (individual size, season, trophic resources and origin of mussels) which are inevitable in natural fluctuant environment. This underlines the importance to take them into account in field study to propose a correct interpretation of biomarker responses.
Collapse
Affiliation(s)
- E Kerambrun
- Université de Reims Champagne-Ardenne, UMR-I 02 SEBIO (Stress Environnementaux et BIOsurveillance des milieux aquatiques), INERIS-URCA-ULH, France.
| | - D Rioult
- Université de Reims Champagne-Ardenne, UMR-I 02 SEBIO (Stress Environnementaux et BIOsurveillance des milieux aquatiques), INERIS-URCA-ULH, France; Université de Reims Champagne-Ardenne/INERIS, Plateau Technique mobile de cytométrie environnementale MOBICYTE, France
| | - L Delahaut
- Université de Reims Champagne-Ardenne, UMR-I 02 SEBIO (Stress Environnementaux et BIOsurveillance des milieux aquatiques), INERIS-URCA-ULH, France
| | - L Evariste
- Université de Reims Champagne-Ardenne, UMR-I 02 SEBIO (Stress Environnementaux et BIOsurveillance des milieux aquatiques), INERIS-URCA-ULH, France; Institut National de la Recherche Scientifique, INRS, Institut Armand Frappier, 531 Boulevard des Prairies, Laval, Quebec, Canada H7V 1B7
| | - S Pain-Devin
- Université de Lorraine, UMR 7360 LIEC (Laboratoire Interdisciplinaire des Environnements Continentaux), CNRS, France
| | - M Auffret
- Université de Bretagne Occidentale, UMR 6539-LEMAR (Laboratoire des Sciences de l'Environnement Marin), IUEM, UBO-CNRS-IRD-Ifremer, F-29280 Plouzane, France
| | - A Geffard
- Université de Reims Champagne-Ardenne, UMR-I 02 SEBIO (Stress Environnementaux et BIOsurveillance des milieux aquatiques), INERIS-URCA-ULH, France
| | - E David
- Université de Reims Champagne-Ardenne, UMR-I 02 SEBIO (Stress Environnementaux et BIOsurveillance des milieux aquatiques), INERIS-URCA-ULH, France
| |
Collapse
|
26
|
Auffret M, Bernard-Phalippon N, Dekemp J, Carlier P, Gervoise Boyer M, Vial T, Gautier S. Misoprostol exposure during the first trimester of pregnancy: Is the malformation risk varying depending on the indication? Eur J Obstet Gynecol Reprod Biol 2016; 207:188-192. [PMID: 27865944 DOI: 10.1016/j.ejogrb.2016.11.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2016] [Revised: 11/03/2016] [Accepted: 11/10/2016] [Indexed: 11/13/2022]
Abstract
OBJECTIVE To report the prospective follow-up of pregnancies exposed to misoprostol during the first trimester and analyse the teratogenic risk depending on the indication for use. STUDY DESIGN Prospective observational study of 265 women exposed to misoprostol during the first 12 weeks of pregnancy and followed until the delivery. Women were included if they or their physician had contacted a French pharmacovigilance centre before 22 weeks of gestation (WG) to obtain information on the risk of misoprostol exposure, and if there had been misoprostol exposure before 13 WG. Data were collected at the time of the first contact, and the pregnancy outcome was recorded at follow-up. Women were prospectively enrolled from January 1988 to December 2013. RESULTS The main indication for misoprostol was voluntary abortion (60.9%). Ten major malformations (5.5%) (95% CI 2.65-9.82%) were reported and five of them were consistent with the pattern of malformations attributed to misoprostol: Möbius sequence, hydrocephalus, terminal transverse limb reduction associated with a clubfoot, syndactyly, and complete posterior encephalocele. The rate of malformations was higher, but not significantly, in women exposed to misoprostol for voluntary abortion (7.9%) compared with women exposed to misoprostol for other or unknown indications (3.2%). CONCLUSIONS Our results confirmed a specific pattern of malformations due to misoprostol use in early pregnancy, even with low dose of misoprostol. Despite the small number of cases, we observed a higher proportion of major malformations in fetuses born to women who continued their pregnancy after a failed voluntary abortion with misoprostol. Further studies should be conducted to evaluate other potential factors, such as combination treatment with mifepristone and the socio-environmental characteristics in this group of women.
Collapse
Affiliation(s)
- Marine Auffret
- Centre Régional de PharmacoVigilance du Nord-Pas de Calais, CHRU de Lille, France.
| | | | - Joëlle Dekemp
- Centre Régional de PharmacoVigilance du Nord-Pas de Calais, CHRU de Lille, France
| | - Patrick Carlier
- Centre Régional de Pharmacovigilance Paris, Hôpital Fernand Widal, AP-HP, France
| | | | - Thierry Vial
- Centre Régional de PharmacoVigilance de Lyon, Hospices Civils de Lyon, France
| | - Sophie Gautier
- Centre Régional de PharmacoVigilance du Nord-Pas de Calais, CHRU de Lille, France
| |
Collapse
|
27
|
Chatelet JN, Auffret M, Combret S, Bondon-Guitton E, Lambert M, Gautier S. [Hydroxychloroquine-induced hearing loss: First case of positive rechallenge and analysis of the French pharmacovigilance database]. Rev Med Interne 2016; 38:340-343. [PMID: 27745936 DOI: 10.1016/j.revmed.2016.07.008] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2016] [Revised: 06/07/2016] [Accepted: 07/30/2016] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Several cases of hearing loss induced by hydroxychloroquine have been reported in the literature but the role of hydroxychloroquine still remains debated. CASE REPORT We report the first case, to our knowledge, of hearing loss induced by hydroxychloroquine with a positive re challenge in a woman treated for systemic lupus. An analysis of the French pharmacovigilance database allowed to identify 23 additional cases of hearing loss in patients treated with hydroxychloroquine and, among them, 8 had systemic lupus. CONCLUSION Despite an excellent tolerance and high efficacy-side effect ratio, this case report adds some evidence for an otoxicity of hydroxychloroquine.
Collapse
Affiliation(s)
- J-N Chatelet
- Centre régional de pharmacovigilance de Lille, CHRU de Lille, 1, place de Verdun, 59045 Lille cedex, France
| | - M Auffret
- Centre régional de pharmacovigilance de Lille, CHRU de Lille, 1, place de Verdun, 59045 Lille cedex, France.
| | - S Combret
- Centre régional de pharmacovigilance de Dijon, CHU de Dijon, 21079 Dijon cedex France
| | - E Bondon-Guitton
- Centre régional de pharmacovigilance de Toulouse, CHU de Toulouse, 31000 Toulouse France
| | - M Lambert
- Service de médecine Interne, hôpital Claude-Huriez, CHRU de Lille, 59045 Lille cedex France
| | - S Gautier
- Centre régional de pharmacovigilance de Lille, CHRU de Lille, 1, place de Verdun, 59045 Lille cedex, France
| |
Collapse
|
28
|
Béné J, Moulis G, Bennani I, Auffret M, Coupe P, Babai S, Hillaire-Buys D, Micallef J, Gautier S. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database. Br J Dermatol 2016; 175:296-301. [PMID: 27031194 DOI: 10.1111/bjd.14601] [Citation(s) in RCA: 120] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/01/2016] [Indexed: 12/11/2022]
Abstract
BACKGROUND Inhibitors of dipeptidyl peptidase (DPP)-IV have been suspected in the onset of bullous pemphigoid for several years now. However, comparative studies assessing the link between DPP-IV inhibitor exposure and bullous pemphigoid have not yet been performed. OBJECTIVES To detect, from the French Pharmacovigilance Database (FPVD), a signal of risk of bullous pemphigoid during DPP-IV inhibitor exposure by comparative study. METHODS All spontaneous reports of DPP-IV inhibitor-related bullous pemphigoid recorded in the FPVD between April 2008 and August 2014 were described. We conducted disproportionality analyses (case-noncase method) to assess the link between DPP-IV inhibitors and bullous pemphigoid, calculating reporting odds ratios (RORs). We also compared DPP-IV inhibitor-induced bullous pemphigoid reports rated per million defined daily doses dispensed during the study period. RESULTS Among 217 331 spontaneous adverse drug reaction reports registered in the FPVD, 1297 involved DPP-IV inhibitors. Among these observations, 42 were bullous pemphigoid (vildagliptin, n = 31; sitagliptin, n = 10; saxagliptin, n = 1). The ROR for pooled DPP-IV inhibitors was 67·5 [95% confidence interval (CI) 47·1-96·9]. Disproportionality was also observed for each DPP-IV inhibitor: vildagliptin (ROR 225·3, 95% CI 148·9-340·9), sitagliptin (ROR 17·0, 95% CI 8·9-32·5) and saxagliptin (ROR 16·5, 95% CI 2·3-119·1). Analyses adjusted on dispensing data led to similar results. CONCLUSIONS These data confirm a strong signal for an increased risk of bullous pemphigoid during DPP-IV inhibitor exposure. This adverse drug reaction is observed for each DPP-IV inhibitor, suggesting a class effect. The signal was higher with vildagliptin than with the other DPP-IV inhibitors.
Collapse
Affiliation(s)
- J Béné
- Centre Régional de Pharmacovigilance du Nord Pas-de-Calais, Univ.Lille, CHU Lille, F-59000, Lille, France
| | - G Moulis
- Service de Médecine Interne, CHU de Toulouse, Toulouse, France.,UMR 1027 INSERM-Université Paul Sabatier, Toulouse, France.,Centre d'Investigation Clinique 1436, CHU de Toulouse, France
| | - I Bennani
- Service de Dermatologie, CHU de Toulouse, Toulouse, France
| | - M Auffret
- Centre Régional de Pharmacovigilance du Nord Pas-de-Calais, Univ.Lille, CHU Lille, F-59000, Lille, France
| | - P Coupe
- Service Pharmacie, Centre Hospitalier de Valenciennes, Valenciennes, France
| | - S Babai
- Centre Régional de PharmacoVigilance, Hôpital Henri Mondor, Assistance Publique Hôpitaux de Paris, Créteil, France
| | - D Hillaire-Buys
- Centre Régional de PharmacoVigilance, Département de Pharmacologie Médicale et Toxicologie, Faculté de Médecine et CHRU, Montpellier, France
| | - J Micallef
- Centre Régional de PharmacoVigilance, Service de Pharmacologie Clinique et Pharmacovigilance, Assistance Publique des Hôpitaux de Marseille, Aix Marseille Université, Marseille, France
| | - S Gautier
- Centre Régional de Pharmacovigilance du Nord Pas-de-Calais, Univ.Lille, CHU Lille, F-59000, Lille, France
| | | |
Collapse
|
29
|
Bigot P, Auffret M, Gautier S, Weinborn M, Ettahar NK, Coupé P. Unexpected platelets elevation in a patient with idiopathic thrombocytopenia treated with oseltamivir for influenza infection. Fundam Clin Pharmacol 2016; 30:483-5. [DOI: 10.1111/fcp.12213] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2016] [Revised: 06/10/2016] [Accepted: 06/23/2016] [Indexed: 11/29/2022]
Affiliation(s)
- Pierre Bigot
- Pharmacy Department; Valenciennes Hospital; Valenciennes France
| | - Marine Auffret
- Regional pharmacovigilance center; Lille University Hospital; Lille France
| | - Sophie Gautier
- Regional pharmacovigilance center; Lille University Hospital; Lille France
| | - Marie Weinborn
- Dermatology Department; Valenciennes Hospital; Valenciennes France
| | - Nicolas-Kader Ettahar
- Infectious and Tropical Diseases Department; Valenciennes Hospital; Valenciennes France
| | - Patrick Coupé
- Pharmacy Department; Valenciennes Hospital; Valenciennes France
| |
Collapse
|
30
|
Rochoy M, Béné J, Messaadi N, Auffret M, Gautier S. Évaluation du site internet du centre régional de pharmacovigilance du Nord-Pas-de-Calais. Therapie 2016; 71:329-33. [DOI: 10.1016/j.therap.2015.10.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2015] [Accepted: 10/08/2015] [Indexed: 11/16/2022]
|
31
|
Akcha F, Barranger A, Bachère E, Berthelin CH, Piquemal D, Alonso P, Sallan RR, Dimastrogiovanni G, Porte C, Menard D, Szczybelski A, Benabdelmouna A, Auffret M, Rouxel J, Burgeot T. Effects of an environmentally relevant concentration of diuron on oyster genitors during gametogenesis: responses of early molecular and cellular markers and physiological impacts. Environ Sci Pollut Res Int 2016; 23:8008-8020. [PMID: 26780042 DOI: 10.1007/s11356-015-5969-2] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/02/2015] [Accepted: 12/10/2015] [Indexed: 06/05/2023]
Abstract
Genitors of the Pacific oyster Crassostrea gigas were submitted during gametogenesis to a short pulse exposure to the herbicide diuron at a realistic environmental concentration. Histological analysis showed no effect of diuron on gametogenesis course, sex ratio and reproductive effort. A non-significant increase in testosterone and progesterone levels was observed in genitors exposed to the herbicide. At cell level, diuron exposure was shown to modulate the phagocytic activity of circulating hemocytes. The results of a transcriptional analysis showed that diuron affected the expression of genes belonging to functions known to play a major role during oyster gametogenesis such as gene transcription regulation, DNA replication and repair, DNA methylation and cytokinesis. Taking into account the results we previously obtained on the same genitors, this study showed a negative effect of diuron on oyster reproduction by inducing both structural and functional modifications of the DNA.
Collapse
Affiliation(s)
- F Akcha
- Laboratoire d'Ecotoxicologie, Ifremer, Rue de l'Ile d'Yeu, BP21105, 44311, Nantes cedex 03, France.
| | - A Barranger
- Laboratoire d'Ecotoxicologie, Ifremer, Rue de l'Ile d'Yeu, BP21105, 44311, Nantes cedex 03, France
| | - E Bachère
- Ifremer, UMR 5244, IHPE Interaction Host Pathogen Environment, UPVD, CNRS, Université de Montpellier, CC 80, F-34095, Montpellier, France
| | - C Heude Berthelin
- Unité Biologie des organismes et écosystèmes aquatiques (BOREA, UMR 7208), Université de Caen Normandie, Sorbonne Universités, Muséum national d'Histoire naturelle, Université Pierre et Marie Curie, CNRS, IRD, 57 rue Cuvier, 75005, Paris, France
| | - D Piquemal
- Acobiom, 1682 rue de la Valsière, CS 77394 Cap Delta Biopole Euromédecine II, 34184, Montpellier Cedex 04, France
| | - P Alonso
- Ifremer, UMR 5244, IHPE Interaction Host Pathogen Environment, UPVD, CNRS, Université de Montpellier, CC 80, F-34095, Montpellier, France
| | - R Rondon Sallan
- Ifremer, UMR 5244, IHPE Interaction Host Pathogen Environment, UPVD, CNRS, Université de Montpellier, CC 80, F-34095, Montpellier, France
| | - G Dimastrogiovanni
- IDAEA-CSIC, Environmental Chemistry Department, C/ Jordi Girona, 1808034, Barcelona, Spain
| | - C Porte
- IDAEA-CSIC, Environmental Chemistry Department, C/ Jordi Girona, 1808034, Barcelona, Spain
| | - D Menard
- Laboratoire d'Ecotoxicologie, Ifremer, Rue de l'Ile d'Yeu, BP21105, 44311, Nantes cedex 03, France
| | - A Szczybelski
- Laboratoire d'Ecotoxicologie, Ifremer, Rue de l'Ile d'Yeu, BP21105, 44311, Nantes cedex 03, France
| | - A Benabdelmouna
- Ifremer, Laboratoire de Génétique et Pathologies, Rue de Mus de Loup, La Tremblade, 17390, France
| | - M Auffret
- Laboratoire des Sciences de l'Environnement Marin (LEMAR), Institut Universitaire Européen de la Mer (IUEM), UBO/CNRS/IRD/IFREMER, rue Dumont d'Urville, technopôle, Brest-Iroise, 29280, Plouzané, France
| | - J Rouxel
- Laboratoire d'Ecotoxicologie, Ifremer, Rue de l'Ile d'Yeu, BP21105, 44311, Nantes cedex 03, France
| | - T Burgeot
- Laboratoire d'Ecotoxicologie, Ifremer, Rue de l'Ile d'Yeu, BP21105, 44311, Nantes cedex 03, France
| |
Collapse
|
32
|
Rolland B, Auffret M, Franchitto N. Safety reports on the off-label use of baclofen for alcohol-dependence: recommendations to improve causality assessment. Expert Opin Drug Saf 2016; 15:747-51. [DOI: 10.1517/14740338.2016.1168397] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Affiliation(s)
- Benjamin Rolland
- Service d’Addictologie, CHU Lille, Lille, France
- Département de Pharmacologie Médicale INSERM U,1171, Univ Lille, Lille, France
| | - Marine Auffret
- Centre Régional de Pharmacovigilance, INSERM U1171, CHU Lille, Lille, France
| | | |
Collapse
|
33
|
Cottin J, Gouraud A, Jean-Pastor MJ, Dautriche AD, Boulay C, Geniaux H, Auffret M, Bernard N, Descotes J, Vial T. Safety profile of etifoxine: A French pharmacovigilance survey. Fundam Clin Pharmacol 2016; 30:147-52. [PMID: 26588183 DOI: 10.1111/fcp.12169] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2015] [Revised: 10/31/2015] [Accepted: 11/13/2015] [Indexed: 11/29/2022]
Abstract
Etifoxine chlorhydrate is a benzoxazine derivative approved for the treatment of psychosomatic manifestations of anxiety since 1979. Previously labeled adverse drug reactions (ADRs) only include drowsiness, benign cutaneous reactions, and acute hypersensitivity reactions. The objectives were to examine recent data on etifoxine-related ADR by reviewing Individual Case Safety Reports (ICSRs) recorded in France especially unexpected ADRs. Etifoxine-related ICSRs were extracted from the French Pharmacovigilance database from 1 January 2000 to 30 April 2012 and data from the marketing authorization holder up to 31 December 2011 were also obtained. Of the 350 cases retained for analysis, 123 (35%) were considered serious. Dermatological or acute hypersensitivity reactions were the most frequent ADRs (59%) mainly isolated cutaneous eruptions. However, there were 24 cases of severe toxidermia (DRESS in 5, erythema multiforme in 10 and Stevens-Johnson syndrome in 5) with etifoxine as the most suspected drug in 11 patients, and seven cases of vasculitis or serum sickness-like reaction. Liver disorders were reported in 34 patients of whom 25 developed acute hepatitis with a cytolytic biological pattern in 16. Other unexpected ADRs included 16 reversible cases of metrorrhagia with positive rechallenge in 5, and three cases of biopsy-proven microscopic colitis of which one recurred after etifoxine re-administration. Although etifoxine has been marketed for more than 30 years, this survey identified a number of unexpected and sometimes serious ADRs, in particularly severe toxidermia and acute cytolytic hepatitis. A recent update of the French etifoxine summary of the product characteristics (SPC) was based on these findings.
Collapse
Affiliation(s)
- Judith Cottin
- Regional Pharmacovigilance Center of Lyon, University Hospitals, 162, avenue Lacassagne, 69003, Lyon, France
| | - Aurore Gouraud
- Regional Pharmacovigilance Center of Lyon, University Hospitals, 162, avenue Lacassagne, 69003, Lyon, France
| | - Marie-Josèphe Jean-Pastor
- Regional Pharmacovigilance Center of Marseille, Hôpital Sainte-Marguerite, University Hospitals (AP-HM), 270, Boulevard de Sainte-Marguerite 13274 Marseille Cedex 09, France
| | - Anne Disson- Dautriche
- Regional Pharmacovigilance Center of Dijon, University Hospitals, 14 rue Paul Gaffarel, 21079 Dijon Cedex, BP 779008, France
| | - Charlène Boulay
- Regional Pharmacovigilance Center of Rouen, University Hospitals, Service de pharmacologie, 76 031 Rouen Cedex, France
| | - Hélène Geniaux
- Regional Pharmacovigilance Center of Bordeaux, University Hospitals, Hôpital Pellegrin, 33076 Bordeaux Cedex, France
| | - Marine Auffret
- Regional Pharmacovigilance Center of Lille, University Hospitals, 1 Place de Verdun, 59045 Lille Cedex, France
| | - Nathalie Bernard
- Regional Pharmacovigilance Center of Lyon, University Hospitals, 162, avenue Lacassagne, 69003, Lyon, France
| | - Jacques Descotes
- Regional Pharmacovigilance Center of Lyon, University Hospitals, 162, avenue Lacassagne, 69003, Lyon, France
| | - Thierry Vial
- Regional Pharmacovigilance Center of Lyon, University Hospitals, 162, avenue Lacassagne, 69003, Lyon, France
| |
Collapse
|
34
|
Beaudry A, Lacaze E, Jobin-Piché A, Masson S, Auffret M, Brousseau P, Fournier M. Ecotoxicological Evaluation of the Immunocompetence of two Bivalves Species ( Mya Arenaria and Mytilus Edulis ) in the Saguenay Fjord Including a Salinity Gradient. J Xenobiot 2015; 5:5769. [PMID: 30701041 PMCID: PMC6324476 DOI: 10.4081/xeno.2015.5769] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Affiliation(s)
| | - E Lacaze
- INRS-Institut-Armand-Frappier, Laval, Québec, Canada
| | - A Jobin-Piché
- Parc Marin Saguenay St-Laurent, Rivière-Éternité, Québec, Canada
| | - S Masson
- Aquarium du Québec, Québec, Canada
| | - M Auffret
- Université de Bretagne Occidentale, Brest, France
| | | | | |
Collapse
|
35
|
Béné J, Moulis G, Bennani I, Auffret M, Gautier S. Pemphigoïdes bulleuses et inhibiteurs de la DiPeptidyl Peptidase-IV : une étude cas/non-cas dans la base nationale de pharmacovigilance. Rev Med Interne 2015. [DOI: 10.1016/j.revmed.2015.10.292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
36
|
Rolland B, Labreuche J, Duhamel A, Deheul S, Gautier S, Auffret M, Pignon B, Valin T, Bordet R, Cottencin O. Baclofen for alcohol dependence: Relationships between baclofen and alcohol dosing and the occurrence of major sedation. Eur Neuropsychopharmacol 2015; 25:1631-6. [PMID: 26095229 DOI: 10.1016/j.euroneuro.2015.05.008] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/24/2015] [Revised: 04/29/2015] [Accepted: 05/25/2015] [Indexed: 11/29/2022]
Abstract
High-dose baclofen, i.e., 300 mg/d or more, has recently emerged as a strategy for treating alcohol dependence. The impact that the co-exposure of large amounts of alcohol and baclofen has on sedation is unclear. In a prospective cohort of 253 subjects with alcohol dependence, we collected daily alcohol and baclofen doses across the first year of baclofen treatment and the monthly maximum subjective sedation experienced by each patient (0-10 visual analog scale). For each patient-month, we determined the average weekly alcohol consumption (AWAC; standard-drinks/week) and the maximum daily dose of baclofen (DDB; mg/d). The occurrence of an episode of major sedation (EMS) during a patient-month was defined as a sedation score ≥7. The relationship between the EMS occurrence and the concurrent AWAC and DDB was investigated using a generalized estimating equation model. In total, 1528 patient-months were compiled (70 with an EMS). Univariate analyses demonstrated that the rate of patient-month to EMS increased gradually with AWAC (p<0.001), from 0.9% for AWAC=0 to 9.4% for AWAC >35. There was also a significant gradual risk for EMS associated with DDB (<0.001). Multivariate analysis demonstrated a significant interaction between DDB and AWAC on EMS risk (p=0.047). Each 20mg/d increase in DDB was associated with an OR of EMS in AWAC >35 of 1.22 (95%CI, 1.08-1.38) versus 1.11 (95%CI, 0.96-1.29) in AWAC=1-35, and 0.95 (95%CI, 0.76-1.19) in AWAC=0. The level of sedation observed in patients using baclofen for alcohol dependence appears to directly depend on the immediate doses of both the baclofen and the alcohol.
Collapse
Affiliation(s)
- Benjamin Rolland
- Department of Addiction Medicine, CHU Lille, F-59037 Lille, France; Department of Pharmacology, INSERM U 1171, Univ Lille, F-59045 Lille, France.
| | | | - Alain Duhamel
- Department of Biostatistics, CHU Lille, F-59037 Lille, France; CERIM, EA 2694, Univ Lille, F-59045 Lille, France
| | | | - Sophie Gautier
- Department of Pharmacology, INSERM U 1171, Univ Lille, F-59045 Lille, France; Department of Pharmacovigilance, F-59037 Lille, France
| | | | - Baptiste Pignon
- Department of Addiction Medicine, CHU Lille, F-59037 Lille, France
| | - Thomas Valin
- Department of Psychiatry, CH Douai F-59507, Douai, France
| | - Régis Bordet
- Department of Pharmacology, INSERM U 1171, Univ Lille, F-59045 Lille, France; CEIP, CHU Lille, F-59037 Lille, France; Department of Pharmacovigilance, F-59037 Lille, France
| | - Olivier Cottencin
- Department of Addiction Medicine, CHU Lille, F-59037 Lille, France; SCALAB UMR CNRS 9193, Univ Lille, F-59045 Lille, France
| |
Collapse
|
37
|
Guyon L, Auffret M, Coussemacq M, Béné J, Deruelle P, Gautier S. Alteration of the Fetal Heart Rate Pattern Induced by the Use Of Clozapine during Pregnancy. Therapie 2015; 70:301-3. [DOI: 10.2515/therapie/2014214] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2014] [Accepted: 10/06/2014] [Indexed: 11/20/2022]
|
38
|
Auffret M, Tyvaert L, Laroche ML, Godet B, Peyron R, Guy C, Géniaux H, Pécriaux C, Baldin B, Béné J, Gautier S. [Drug Shortage May Have Serious Outcome: the French Exemple of Phenytoine]. Therapie 2015; 70:377-80. [PMID: 25882102 DOI: 10.2515/therapie/2015018] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2014] [Accepted: 12/15/2014] [Indexed: 11/20/2022]
Abstract
In 2012, in France, phenytoin sodium was used as a substitute for phenytoin base during a shortage at the dose of 100 mg for 100 mg, according to the French Health Agency recommendations. However, this substitution was problematic because the two specialties were not bioequivalent. We report here the case of a 29-year old woman who presented with severe epilepsy. The substitution of phenytoin base by phenytoin sodium induced an increase of seizure frequency leading to several hospitalizations and sick leave. Phenytoin base was finally available again in 2013 which allowed a reduction of seizure frequency. Six similar cases, including one death, were reported to the French pharmacovigilance system. Drug shortages are increasingly common and can have serious consequences. Reporting the difficulties that drug shortage causes to health authorities is important in order to improve their management and to better support patients.
Collapse
Affiliation(s)
- Marine Auffret
- Centre Régional de Pharmacovigilance, CHRU, Lille, France
| | - Louise Tyvaert
- Service de Neurophysiologie Clinique, CHRU, Lille, France
| | | | | | | | - Claire Guy
- Centre Régional de Pharmacovigilance, CHU, Saint-Etienne, France
| | - Hélène Géniaux
- Centre Régional de Pharmacovigilance, CHU, Bordeaux, France
| | - Caroline Pécriaux
- Centre Régional de Pharmacovigilance Saint Vincent de Paul, AP-HP, Paris, France
| | | | - Johana Béné
- Centre Régional de Pharmacovigilance, CHRU, Lille, France
| | - Sophie Gautier
- Centre Régional de Pharmacovigilance, CHRU, Lille, France
| |
Collapse
|
39
|
Rolland B, Deheul S, Danel T, Bence C, Blanquart MC, Bonord A, Semal R, Briand T, Sochala M, Dubocage C, Dupriez F, Duquesne D, Gibour B, Loosfeld X, Henebelle D, Henon M, Vernalde E, Matton C, Bacquet JE, Molmy L, Sarasy F, Simioni N, Richez C, Gentil-Spinosi L, Vosgien V, Yguel J, Ledent T, Auffret M, Wilquin M, Ziolkowski D, Sochala M, Gautier S, Bordet R, Cottencin O. La « recommandation temporaire d’utilisation » sur le baclofène : point de vue des prescripteurs du dispositif CAMTEA. Therapie 2015; 70:235-8. [DOI: 10.2515/therapie/2014210] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2014] [Accepted: 10/03/2014] [Indexed: 11/20/2022]
|
40
|
Auffret M, Rolland B, Caous AS, Deheul S, Béné J, Cottencin O, Bordet R, Gautier S. Attitudes of community pharmacists to off-label prescribing of baclofen in Northern France. Int J Clin Pharm 2015; 37:296-9. [PMID: 25666941 DOI: 10.1007/s11096-015-0074-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2014] [Accepted: 01/27/2015] [Indexed: 10/24/2022]
Abstract
BACKGROUND Community pharmacists' liability is involved when they dispense off-label prescriptions (OLPs). However, their attitudes to off-label prescribing are little known, while in France off-label baclofen use for alcohol dependence is increasing. OBJECTIVE To determine community pharmacists' attitudes to off-label prescribing of baclofen. METHOD A postal questionnaire was sent to 219 community pharmacies in the Nord-Pas-de-Calais region, France, previously identified as delivering at least five boxes of oral baclofen monthly. The questionnaire examined whether pharmacists delivered baclofen for alcohol dependence, how pharmacists detected off-label prescribing of baclofen, who were the most frequent prescribers (general practitioners or specialists), and pharmacists' attitudes to OLPs. RESULTS Eighty pharmacies responded (36.5 %). Detection criteria for OLPs were supra-threshold dose (77.3 %) and "off-label" written on prescription (52.5 %). General practitioners were the most frequent prescribers of off-label baclofen. Pharmacists were more likely to refuse to fill prescriptions not marked "off-label" (6.0 %) than correctly marked prescriptions (1.5 %). 85 % of respondents considered they lacked information on off-label use. CONCLUSION Although community pharmacists felt they were poorly informed on off-label baclofen, the majority nevertheless delivered the drug. Since our survey, off-label baclofen prescribing has been strictly controlled in France. Pharmacists' current attitudes will need further evaluation.
Collapse
Affiliation(s)
- Marine Auffret
- Centre Régional de Pharmacovigilance, CHRU de Lille, 59037, Lille Cedex, France,
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Béné J, Auffray JL, Auffret M, Caron J, Gautier S. Aortic dissection during rivaroxaban therapy: a challenging care. Acta Anaesthesiol Scand 2015; 59:268. [PMID: 25394590 DOI: 10.1111/aas.12438] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
42
|
Rossi M, Auffret M, Bastides M, Faucon M, Béné J, Gautier S. Tamoxifène : une prescription surprenante chez un bodybuilder. Presse Med 2015; 44:247-9. [DOI: 10.1016/j.lpm.2014.08.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/16/2014] [Revised: 07/15/2014] [Accepted: 08/25/2014] [Indexed: 10/24/2022] Open
|
43
|
Auffret M, Béné J, Lambert M, Gautier S. [Mesalazine-related interstitial lung disease: an under-diagnosed effect?]. Therapie 2014; 69:531-2. [PMID: 25320942 DOI: 10.2515/therapie/2014205] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2014] [Accepted: 09/03/2014] [Indexed: 11/20/2022]
Abstract
We report the case of a woman treated with adalimumab and mesalazine for a Crohn's disease who presented 9 years after the beginning of the treatments an interstitial lung disease (ILD) discovered by chance during a routine medical examination. Several hypotheses were evocated: progression of the Crohn's disease with a pulmonary involvement then the role of adalimumab was finally suspected. Adalimumab treatment was stopped, but several months later, the pulmonary disease persisted. Six months after the initial medical consult, mesalazine treatment was suspected and stopped. The ILD improved and finally completely resolved with no recurrence after one year. Interstitial lung disease is a rare side effect of mesalazine probably underdiagnosed by physicians especially in patients treated with TNF alpha inhibitors.
Collapse
Affiliation(s)
- Marine Auffret
- Centre régional de pharmacovigilance du Nord-Pas-de-Calais, CHRU Lille, Lille, France
| | - Johana Béné
- Centre régional de pharmacovigilance du Nord-Pas-de-Calais, CHRU Lille, Lille, France
| | - Marc Lambert
- Service de médecine interne, CHRU Lille, Lille, France
| | - Sophie Gautier
- Centre régional de pharmacovigilance du Nord-Pas-de-Calais, CHRU Lille, Lille, France
| |
Collapse
|
44
|
Béné J, Gantois E, Landouzy M, Auffret M, Coupé P, Courouble M, Gautier S. [Ecchymosis during montelukast therapy: about one case]. Therapie 2014; 69:517-8. [PMID: 25270304 DOI: 10.2515/therapie/2014058] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2014] [Accepted: 06/02/2014] [Indexed: 11/20/2022]
Abstract
A young girl aged 13-years-old treated with montelukast, fluticasone/salmeterol, desloratadine, fluticasone furoate and salbutamol has presented numerous spontaneous bruises after that treatment with montelukast was substituted by the generic form. Stopping montelukast allow a significant improvement in bruises.
Collapse
Affiliation(s)
- Johana Béné
- Centre régional de pharmacovigilance, Service de pharmacologie médicale, CHRU Lille, Lille, France
| | - Emeline Gantois
- Service pharmacie, Centre hospitalier de Valenciennes, Valenciennes, France
| | - Marion Landouzy
- Service pharmacie, Centre hospitalier de Valenciennes, Valenciennes, France
| | - Marine Auffret
- Centre régional de pharmacovigilance, Service de pharmacologie médicale, CHRU Lille, Lille, France
| | - Patrick Coupé
- Service pharmacie, Centre hospitalier de Valenciennes, Valenciennes, France
| | - Mélanie Courouble
- Service de pneumologie pédiatrique, Centre hospitalier de Valenciennes, Valenciennes, France
| | - Sophie Gautier
- Centre régional de pharmacovigilance, Service de pharmacologie médicale, CHRU Lille, Lille, France
| |
Collapse
|
45
|
Béné J, Bastides M, Auffret M, Gautier S. Serotonin and yawning: A possible adverse drug reaction during antidepressant therapy. Presse Med 2014; 43:1135-6. [DOI: 10.1016/j.lpm.2013.12.018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/16/2013] [Revised: 12/13/2013] [Accepted: 12/19/2013] [Indexed: 11/25/2022] Open
|
46
|
Béné J, Alarcon P, Faucon M, Auffret M, Delfosse F, Becker T, De Zorzi S, Gautier S. Anaphylactic shock after misoprostol in voluntary termination of pregnancy—a case report. Eur J Obstet Gynecol Reprod Biol 2014; 182:260-1. [PMID: 25264135 DOI: 10.1016/j.ejogrb.2014.09.012] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2014] [Accepted: 09/03/2014] [Indexed: 10/24/2022]
Affiliation(s)
- Johana Béné
- Centre Régional de Pharmacovigilance, Centre Hospitalier de Lille, Faculté de Médecine, Université Lille 2, Lille, France.
| | - Philippe Alarcon
- Service des Urgences, Centre Hospitalier Sambre Avesnois, 13 Boulevard Pasteur, 59607 Maubeuge, France
| | - Marina Faucon
- Centre Régional de Pharmacovigilance, Centre Hospitalier de Lille, Faculté de Médecine, Université Lille 2, Lille, France
| | - Marine Auffret
- Centre Régional de Pharmacovigilance, Centre Hospitalier de Lille, Faculté de Médecine, Université Lille 2, Lille, France
| | - Fleur Delfosse
- Pharmacie, Centre Hospitalier Sambre Avesnois, 13 Boulevard Pasteur, 59607 Maubeuge, France
| | - Tobias Becker
- Service de Soins Continus, Centre Hospitalier Sambre Avesnois, 13 Boulevard Pasteur, 59607 Maubeuge, France
| | - Sylvio De Zorzi
- Pharmacie, Centre Hospitalier Sambre Avesnois, 13 Boulevard Pasteur, 59607 Maubeuge, France
| | - Sophie Gautier
- Centre Régional de Pharmacovigilance, Centre Hospitalier de Lille, Faculté de Médecine, Université Lille 2, Lille, France
| |
Collapse
|
47
|
Lacroix C, Coquillé V, Guyomarch J, Auffret M, Moraga D. A selection of reference genes and early-warning mRNA biomarkers for environmental monitoring using Mytilus spp. as sentinel species. Mar Pollut Bull 2014; 86:304-313. [PMID: 25037875 DOI: 10.1016/j.marpolbul.2014.06.049] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/28/2014] [Revised: 06/21/2014] [Accepted: 06/25/2014] [Indexed: 06/03/2023]
Abstract
mRNA biomarkers are promising tools for environmental health assessment and reference genes are needed to perform relevant qPCR analyses in tissue samples of sentinel species. In the present study, potential reference genes and mRNA biomarkers were tested in the gills and digestive glands of native and caged mussels (Mytilus spp.) exposed to harbor pollution. Results highlighted the difficulty to find stable reference genes in wild, non-model species and suggested the use of normalization indices instead of single genes as they exhibit a higher stability. Several target genes were found differentially expressed between mussel groups, especially in gills where cyp32, π-gst and CuZn-sod mRNA levels could be biomarker candidates. Multivariate analyses confirmed the ability of mRNA levels to highlight site-effects and suggested the use of several combined markers instead of individual ones. These findings support the use of qPCR technology and mRNA levels as early-warning biomarkers in marine monitoring programs.
Collapse
Affiliation(s)
- C Lacroix
- LEMAR, UMR 6539, Institut Universitaire Européen de la Mer, 29280 Plouzané, France.
| | - V Coquillé
- LEMAR, UMR 6539, Institut Universitaire Européen de la Mer, 29280 Plouzané, France
| | - J Guyomarch
- CEDRE, 715, Rue Alain Colas, CS 41836, 29218 Brest Cedex 2, France
| | - M Auffret
- LEMAR, UMR 6539, Institut Universitaire Européen de la Mer, 29280 Plouzané, France
| | - D Moraga
- LEMAR, UMR 6539, Institut Universitaire Européen de la Mer, 29280 Plouzané, France
| |
Collapse
|
48
|
Comte H, Béné J, Auffret M, Gautier S, Salle-Staumont D. Prise de poids lors d’un traitement par thalidomide : à propos d’un cas. Therapie 2014; 69:457-9. [DOI: 10.2515/therapie/2014055] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2014] [Accepted: 05/05/2014] [Indexed: 11/20/2022]
|
49
|
Béné J, Moulis G, Auffret M, Lefevre G, Coquerelle P, Coupe P, Péré P, Gautier S. Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database. Rheumatology (Oxford) 2014; 53:1465-9. [PMID: 24681837 DOI: 10.1093/rheumatology/keu145] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
OBJECTIVES The aim of this research was to describe the cases of TNF-α antagonist-related alopecia reported in the French Pharmacovigilance Database (FPVD) and to investigate the association between exposure to TNF-α antagonists and occurrence of alopecia. METHODS All spontaneous reports of TNF-α antagonist-related alopecia recorded in the FPVD between January 2000 and April 2012 were colligated and described. We conducted disproportionality analyses (case/non-case method) to assess the link between the occurrence of alopecia and exposure to TNF-α antagonists. Cases were all reports of alopecia and non-cases were all other reports recorded during the study period. Exposure to TNF-α antagonists was sought in cases and in non-cases. Reporting odds ratios (RORs) were calculated to assess the association. Docetaxel was used as positive control and acetaminophen as negative control. We performed sensitivity analyses excluding cases of androgenic alopecia and those occurring in psoriatic patients. RESULTS Among 282 590 spontaneous reports of adverse drug reactions (ADRs) collated in the FPVD, 1068 cases (alopecia reports) were identified. Of these cases, 52 (4.9%) occurred during exposure to TNF-α antagonists (18 involved infliximab, 17 adalimumab, 15 etanercept and 2 certolizumab). Exposure to TNF-α antagonists was more frequent among alopecia reports than among other ADR reports for all TNF-α antagonists pooled (ROR 3.0, 95% CI 2.3, 4.0) as well as for each antagonist separately, with similar values. Sensitivity analyses yielded similar results. The RORs were 29.9 (95% CI 25.3, 35.5) with docetaxel and 0.3 (95% CI 0.2, 0.4) with acetaminophen. CONCLUSION The present study confirms a strong link between TNF-α antagonist exposure (class effect) and the occurrence of alopecia.
Collapse
Affiliation(s)
- Johana Béné
- Regional Centre of Pharmacovigilance, Lille University Hospital, University of Lille 2, Lille, Internal Medicine Department, Toulouse University Hospital, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, Internal Medicine and Clinical Immunology Department, Lille University Hospital, Immunology Laboratory EA2686, Lille University Hospital, Lille, Rheumatology Department, Bethune Hospital, Bethune, Department of Pharmacy, Valenciennes Hospital, Valenciennes and Rheumatology Department, Nancy University Hospital, Nancy, France.Regional Centre of Pharmacovigilance, Lille University Hospital, University of Lille 2, Lille, Internal Medicine Department, Toulouse University Hospital, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, Internal Medicine and Clinical Immunology Department, Lille University Hospital, Immunology Laboratory EA2686, Lille University Hospital, Lille, Rheumatology Department, Bethune Hospital, Bethune, Department of Pharmacy, Valenciennes Hospital, Valenciennes and Rheumatology Department, Nancy University Hospital, Nancy, France.
| | - Guillaume Moulis
- Regional Centre of Pharmacovigilance, Lille University Hospital, University of Lille 2, Lille, Internal Medicine Department, Toulouse University Hospital, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, Internal Medicine and Clinical Immunology Department, Lille University Hospital, Immunology Laboratory EA2686, Lille University Hospital, Lille, Rheumatology Department, Bethune Hospital, Bethune, Department of Pharmacy, Valenciennes Hospital, Valenciennes and Rheumatology Department, Nancy University Hospital, Nancy, France.Regional Centre of Pharmacovigilance, Lille University Hospital, University of Lille 2, Lille, Internal Medicine Department, Toulouse University Hospital, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, Internal Medicine and Clinical Immunology Department, Lille University Hospital, Immunology Laboratory EA2686, Lille University Hospital, Lille, Rheumatology Department, Bethune Hospital, Bethune, Department of Pharmacy, Valenciennes Hospital, Valenciennes and Rheumatology Department, Nancy University Hospital, Nancy, France.Regional Centre of Pharmacovigilance, Lille University Hospital, University of Lille 2, Lille, Internal Medicine Department, Toulouse University Hospital, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, Internal Medicine and Clinical Immunology Department, Lille University Hospital, Immunology Laboratory EA2686, Lille University Hospital, Lille, Rheumatology Department, Bethune Hospital, Bethune, Department of Pharmacy, Valenciennes Hospital, Valenciennes and Rheumatology Department, Nancy University Hospital, Nancy, France
| | - Marine Auffret
- Regional Centre of Pharmacovigilance, Lille University Hospital, University of Lille 2, Lille, Internal Medicine Department, Toulouse University Hospital, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, Internal Medicine and Clinical Immunology Department, Lille University Hospital, Immunology Laboratory EA2686, Lille University Hospital, Lille, Rheumatology Department, Bethune Hospital, Bethune, Department of Pharmacy, Valenciennes Hospital, Valenciennes and Rheumatology Department, Nancy University Hospital, Nancy, France.Regional Centre of Pharmacovigilance, Lille University Hospital, University of Lille 2, Lille, Internal Medicine Department, Toulouse University Hospital, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, Internal Medicine and Clinical Immunology Department, Lille University Hospital, Immunology Laboratory EA2686, Lille University Hospital, Lille, Rheumatology Department, Bethune Hospital, Bethune, Department of Pharmacy, Valenciennes Hospital, Valenciennes and Rheumatology Department, Nancy University Hospital, Nancy, France
| | - Guillaume Lefevre
- Regional Centre of Pharmacovigilance, Lille University Hospital, University of Lille 2, Lille, Internal Medicine Department, Toulouse University Hospital, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, Internal Medicine and Clinical Immunology Department, Lille University Hospital, Immunology Laboratory EA2686, Lille University Hospital, Lille, Rheumatology Department, Bethune Hospital, Bethune, Department of Pharmacy, Valenciennes Hospital, Valenciennes and Rheumatology Department, Nancy University Hospital, Nancy, France.Regional Centre of Pharmacovigilance, Lille University Hospital, University of Lille 2, Lille, Internal Medicine Department, Toulouse University Hospital, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, Internal Medicine and Clinical Immunology Department, Lille University Hospital, Immunology Laboratory EA2686, Lille University Hospital, Lille, Rheumatology Department, Bethune Hospital, Bethune, Department of Pharmacy, Valenciennes Hospital, Valenciennes and Rheumatology Department, Nancy University Hospital, Nancy, France
| | - Pascal Coquerelle
- Regional Centre of Pharmacovigilance, Lille University Hospital, University of Lille 2, Lille, Internal Medicine Department, Toulouse University Hospital, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, Internal Medicine and Clinical Immunology Department, Lille University Hospital, Immunology Laboratory EA2686, Lille University Hospital, Lille, Rheumatology Department, Bethune Hospital, Bethune, Department of Pharmacy, Valenciennes Hospital, Valenciennes and Rheumatology Department, Nancy University Hospital, Nancy, France
| | - Patrick Coupe
- Regional Centre of Pharmacovigilance, Lille University Hospital, University of Lille 2, Lille, Internal Medicine Department, Toulouse University Hospital, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, Internal Medicine and Clinical Immunology Department, Lille University Hospital, Immunology Laboratory EA2686, Lille University Hospital, Lille, Rheumatology Department, Bethune Hospital, Bethune, Department of Pharmacy, Valenciennes Hospital, Valenciennes and Rheumatology Department, Nancy University Hospital, Nancy, France
| | - Patrice Péré
- Regional Centre of Pharmacovigilance, Lille University Hospital, University of Lille 2, Lille, Internal Medicine Department, Toulouse University Hospital, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, Internal Medicine and Clinical Immunology Department, Lille University Hospital, Immunology Laboratory EA2686, Lille University Hospital, Lille, Rheumatology Department, Bethune Hospital, Bethune, Department of Pharmacy, Valenciennes Hospital, Valenciennes and Rheumatology Department, Nancy University Hospital, Nancy, France
| | - Sophie Gautier
- Regional Centre of Pharmacovigilance, Lille University Hospital, University of Lille 2, Lille, Internal Medicine Department, Toulouse University Hospital, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, Internal Medicine and Clinical Immunology Department, Lille University Hospital, Immunology Laboratory EA2686, Lille University Hospital, Lille, Rheumatology Department, Bethune Hospital, Bethune, Department of Pharmacy, Valenciennes Hospital, Valenciennes and Rheumatology Department, Nancy University Hospital, Nancy, France.Regional Centre of Pharmacovigilance, Lille University Hospital, University of Lille 2, Lille, Internal Medicine Department, Toulouse University Hospital, University of Toulouse, UMR INSERM-UPS 1027, Toulouse, Internal Medicine and Clinical Immunology Department, Lille University Hospital, Immunology Laboratory EA2686, Lille University Hospital, Lille, Rheumatology Department, Bethune Hospital, Bethune, Department of Pharmacy, Valenciennes Hospital, Valenciennes and Rheumatology Department, Nancy University Hospital, Nancy, France
| |
Collapse
|
50
|
Lacroix C, Le Cuff N, Receveur J, Moraga D, Auffret M, Guyomarch J. Development of an innovative and “green” stir bar sorptive extraction–thermal desorption–gas chromatography–tandem mass spectrometry method for quantification of polycyclic aromatic hydrocarbons in marine biota. J Chromatogr A 2014; 1349:1-10. [DOI: 10.1016/j.chroma.2014.04.094] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2014] [Revised: 04/28/2014] [Accepted: 04/29/2014] [Indexed: 10/25/2022]
|